Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181620 | 1.00 | NPSR1 (0.39) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25005896 | 0.94 | NPSR1 (0.41) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30224274 | 0.94 | NPSR1 (0.41) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23994719 | 0.91 | NPSR1 (0.39) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30224893 | 0.90 | NPSR1 (0.41) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23994494 | 0.89 | NPSR1 (0.40) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30224427 | 0.89 | NPSR1 (0.40) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30224462 | 0.88 | NPSR1 (0.42) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23994436 | 0.88 | NPSR1 (0.37) | NPSR1ATMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30224848 | 0.88 | NPSR1 (0.37) | NPSR1ATMMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | NPSR1 1783/4885ATM 1522/4885MEN1 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.